Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

FDA Approves Kirsty as First Interchangeable Insulin Aspart Biosimilar

July 15th 2025

By Skylar Jeremias

The FDA has approved Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.

White Paper Offers Tips for Sustaining Biosimilar Progress, Avoiding a Market Void

July 15th 2025

By Skylar Jeremias

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced education to ensure market sustainability.

BioRationality: How the FDA Can Bypass Congress to Change Biosimilar Guidance

July 14th 2025

By Sarfaraz K. Niazi, PhD

Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmD

July 14th 2025

By Cameron Santoro

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more convenient subcutaneous option.

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11th 2025

By Aislinn Antrim

The Top 5 Biosimilar Articles for the Week of July 7

July 11th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of July 7, 2025.

Two More Pairs of Denosumab Biosimilars Enter US Market

July 9th 2025

By Skylar Jeremias

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and bone-related metastases.

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 8th 2025

By Skylar Jeremias

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 7th 2025

By Skylar Jeremias

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 5th 2025

By Deana Ferreri, PhD

Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for patients with inflammatory bowel disease (IBD).